Moderna (NASDAQ: MRNA) reported Q3 EPS of ($9.53), which may not compare to the analyst estimate of ($1.90). Revenue for the quarter came in at $1.8 billion versus the consensus estimate of $1.4 billion.

Company has significantly improved future cost of sales by resizing its manufacturing capacity, contributing to a third quarter net loss of $3.6 billion, primarily driven by mostly non-cash charges of $3.1 billion related to resizing and a tax valuation allowance.

GUIDANCE:

Moderna sees FY2023 revenue of at least $6 billion, versus the consensus of $6.45 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.